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Abstract: Adipokines play an important role in the regulation of glucose metabolism. We have
previously shown that carnosine supplementation in overweight or obese non-diabetic individuals
improves glucose metabolism but does not change adiponectin concentrations. However, its effect on
other adipokines has not been investigated. Herein we further determined the effect of carnosine
supplementation on serum adipsin, resistin and leptin. Twenty-two overweight or obese otherwise
healthy adults were randomly assigned to receive either 2 g of carnosine (n = 13) or identically looking
placebo (n = 9) for 12 weeks. Serum adipsin, leptin and resistin were analyzed using a bead-based
multiplex assay. Carnosine supplementation decreased serum resistin concentrations compared to
placebo (mean change from baseline: −35 ± 83 carnosine vs. 35 ± 55 ng/mL placebo, p = 0.04).
There was a trend for a reduction in serum leptin concentrations after carnosine supplementation
(−76 ± 165 ng/mL carnosine vs. 20 ± 28 ng/mL placebo, p = 0.06). The changes in leptin and resistin
concentrations were inversely related to the change in concentration for urinary carnosine (r = −0.72,
p = 0.0002; r = −0.67, p = 0.0009, respectively), carnosine-propanal (r = −0.56, p = 0.005; r = −0.63,
p = 0.001, respectively) and carnosine-propanol (r =−0.61, p = 0.002; r =−0.60, p = 0.002, respectively).
There were no differences between groups in change in adipsin concentrations. Our findings show
carnosine supplementation may normalize some, but not all, of the serum adipokine concentrations
involved in glucose metabolism, in overweight and obese individuals. Further clinical trials with
larger samples are needed to confirm these results.
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1. Introduction
Adipokines are bioactive peptides that are secreted by adipose tissue [1]. Disruption of
normal adipose tissue function due to excess abdominal fat accumulation, as observed in
obesity, leads to dysregulated production of adipokines [1,2]. Consequently, concentrations of
adipokines in the bloodstream are altered. Although the exact mechanisms remain unclear,
altered adipokines concentrations have been shown to induce inflammation and impair glucose
and lipid metabolism [3,4], thereby contributing to the development of obesity-related chronic diseases
including cardiometabolic [5,6] and neurodegenerative diseases [7]. Adipokines have been shown
to have systemic effects on target organs important for glucose metabolism and heart disease [8],
including the brain, heart, muscle, liver, and pancreas [6], and also have a role in the regulation
of appetite, satiety, and energy expenditure [4]. Adipokines have been proposed not only as novel
biomarkers but also as regulators or potential targets of cardiometabolic and other chronic diseases [4,9].
Therefore, interventions which target adipokines may be beneficial in the treatment of obesity-related
chronic diseases [4].
Carnosine, an over-the-counter food supplement composed of β-alanine and L-histidine
molecules, has been shown to ameliorate cardiometabolic risk factors and diseases by reducing
inflammation, oxidative stress, and advanced glycation, as demonstrated by several animal
studies [10–14]. Supplementation with carnosine has therefore been suggested as a potential strategy
for prevention and treatment of cardiometabolic disease [15–17]. However, there is little evidence from
human studies examining the efficacy of carnosine supplementation in reducing cardiometabolic risk
factors [16–19]. We have previously shown that carnosine supplementation hampered an increase
in insulin resistance and improved glucose tolerance, but had no effect on circulating adiponectin
concentrations [16]. To our knowledge, the effects of carnosine on other adipokines have not previously
been investigated. Therefore, we aimed to address this knowledge gap by examining whether, in a
high-risk group of overweight or obese sedentary individuals, supplementation with carnosine would
reduce serum resistin, leptin, and adipsin concentrations, all of which have been associated with
chronic low-grade inflammation and cardiometabolic diseases [9].
2. Materials and Methods
2.1. Study Design and Participants
This study is a secondary analysis of data from a pilot randomized, double-blind,
placebo-controlled trial which was performed in 30 overweight and obese sedentary individuals.
The trial was conducted at the Institute of Experimental Endocrinology, Slovak Academy of Sciences,
Slovakia, and detailed study methods as well as the primary outcomes have been published [16].
Briefly, study participants were recruited from the community in Bratislava, Slovakia from September
to October 2013 via newspaper advertisements. Participants were enrolled in the study if they were
non-smokers and did not use illicit drugs or take any medications or food supplements, and were
non-diabetic based on a 75 g oral glucose tolerance test (OGTT). All participants were overweight
or obese (body mass index (BMI) ≥ 25 kg/m2) and did not participate in any regular structured
physical activity, but otherwise healthy based on physical examination and routine blood analyses.
All participants were advised to maintain their usual diet and exercise habits and those who had
a weight change ≥5 kg over the 12 week study period were excluded. Participants with clinical or
laboratory signs of infection or acute inflammation were excluded for the purpose of this analysis.
The study protocol conforms to principles of the Declaration of Helsinki and was approved by
the Ethics Committee of the University Hospital Bratislava, Comenius University, Bratislava, Slovakia.
All participants provided written informed consent prior to participation.
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2.2. Intervention and Outcome Measures
Participants were randomly allocated to receive either 1 g carnosine twice daily (Flamma
S.p.A, Bergamo, Italy) or matching placebo (1 g sucrose) for 12 weeks. Participants, investigators,
and outcome assessors were blinded to group assignment until after primary data analysis was
complete. Eligible participants underwent a study protocol which has been described in detail [16].
In brief, the protocol included anthropometric assessments, blood pressure and lipid profile
measurements, OGTT, and assessment of biochemical parameters including urinary carnosine,
carnosinase-1 content and activity, high-sensitivity C-reactive protein (hsCRP) and circulating serum
adipokine concentrations including leptin, resistin, and adipsin. Prior to metabolic testing, participants
were asked to refrain from strenuous exercise and caffeine for 3 days. All metabolic testing and blood
and urine collections were performed under blinded conditions after a 12 h overnight fast (with no
carnosine ingestion for 12 h).
2.3. Anthropometric Measurements
Body weight and height were measured and used to calculate BMI (weight (kg)/square of
height (m)). Waist circumference was measured at the midpoint between the lower border of the rib
cage and the iliac crest in the horizontal plane. While the subjects were standing, hip circumference was
measured at the point yielding the maximum circumference over the buttocks. These measurements
were used to calculate waist-to-hip ratio as an additional index for body fat distribution (waist (cm)/hip
(cm) = waist-to-hip ratio).
2.4. Measurement of Adipokines and hsCRP
Serum adipokines including adipsin, leptin, and resistin were quantified simultaneously by a
bead-based multiplex assay (LEGENDplex™ Human Metabolic Panel, Cat. No. 740212, BioLegend,
San Diego, CA, USA). This assay uses distinguishing bead populations which bind to the specified
analyte, and are differentiated by a LSRII Fortessa flow cytometer (Becton Dickinson (BD), San Diego,
CA, USA). Serum samples were diluted 200-fold as per manufacturer’s instructions and based on
preliminary testing. Standards and serum samples were mixed with sonicated pre-mixed beads and
detection antibodies in a 96-well v-bottom plate and incubated in the dark on a plate shaker (600 rpm,
2 h, room temperature (RT)). Streptavidin–phycoerythrin (SA-PE) conjugate was added to each well,
and the plate was further incubated in the dark on a plate shaker (600 rpm, 30 min, RT). The beads
were centrifuged and pelleted, and further re-suspended in wash buffer. The samples were transferred
to micro FACS tubes and read on a LSRII flow cytometer (BD, San Diego, CA, USA) and analyzed using
FACS DIVA software (BD, San Diego, CA ,USA). Data were analyzed with the provided LegendPlex™
Data Analysis Software (BioLegend, San Diego, CA, USA) with standard curves generated from
0 to 200,000 pg/mL and samples adjusted for dilution factors. Intra- and inter-assay coefficients of
variation (CVs) for the analytes were <7%. Serum hsCRP was measured by an immunoturbidimetric
assay (Randox, UK). Intra- and inter-assay CVs for hsCRP were <10%.
2.5. Measurement of Urinary Carnosine and Carnosine Adducts, and Serum Carnosinase Content and Activity
Carnosine and carnosine adducts were measured in urine using an internal standard and a
triple quadrupole mass spectrometer (TSQ Quantum Ultra, Thermo Scientific, Rodano, Italy) [20].
Carnosinase activity in serum was quantified by fluorometric determination of liberated histidine
after carnosine addition), as previously reported [16]. Serum carnosinase content was measured
using a sandwich enzyme-linked immunosorbent assay (ELISA) developed by Adelmann et al. [21],
as per instructions.
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2.6. Statistical Analysis
The sample size calculation has been reported elsewhere [16], and was based on the primary
outcome of insulin sensitivity. Results are reported as means and standard deviations unless
otherwise specified. Independent Student’s t-tests or Mann–Whitney tests were used to compare
participants’ baseline characteristics between groups for normally and non-normally distributed
variables, respectively. Due to the skewed distributions of the adipokines, all results for the
adipokines analyses were assessed using non-parametric tests. Spearman correlations were used
to examine relationships between change in adipokines and change in carnosine concentrations in the
entire sample. Quantile regression analyses were performed to determine the associations between
adipokines and urinary carnosine measurements after adjusting for predetermined clinically relevant
factors including age, sex, change in BMI, and intervention group. Change in outcomes within each
group (within-group difference from baseline to follow up) was assessed using Wilcoxon signed
rank tests. Differences in change values between groups were determined using Mann–Whitney tests.
Data analyses were performed using Stata V.14 (StatCorp, LP, College Station, TX, USA) and a two-sided
p < 0.05 was considered statistically significant.
3. Results
Of the thirty participants included in the study, three (1 carnosine, 2 placebo) were excluded due
to non-compliance with the protocol [16]. An additional five participants (2 carnosine, 3 placebo),
had unusually high concentrations of plasma inflammatory markers, as measured by hsCRP,
and hence were also excluded. The remaining twenty-two participants were included in the analysis,
with 13 (10 M/3 F) in the carnosine group and 9 (8 M/1 F) in placebo. The mean age ± standard
deviation of participants was 43.4 ± 8.1 years with no significant difference between groups (p = 0.7).
There were no differences between groups in baseline anthropometric measures including BMI
(31.03 ± 4.21 kg/m2 carnosine vs. 31.45 ± 3.62 kg/m2 placebo, p = 0.8) and waist-to-hip ratio
(0.89 ± 0.06 carnosine vs. 0.89 ± 0.07 placebo, p = 0.8). No differences between carnosine and placebo
groups were observed for baseline cardiometabolic and carnosine measures (all p > 0.06) or for serum
adipsin, leptin, and resistin concentrations (Table 1).
Table 1. Effect of carnosine supplementation on serum adipokine concentrations.
Parameters
Carnosine Group (n = 13) Placebo Group (n = 9) ChangeDifference p # p ¶
Baseline Follow up p * Change Baseline Follow up p * Change Mean± SE
Adipsin
(ug/mL)
5.22 ±
4.30 2.61 ± 0.79 0.15
−2.60 ±
4.51
2.89 ±
2.03 3.61 ± 3.57 0.67
0.72 ±
3.82 −3.33 ± 1.84 0.13 0.17
Leptin
(ng/mL)
114.97 ±
146.45
38.75 ±
40.42 0.14
−76.21 ±
165.69
34.60 ±
52.22
70.12 ±
55.74 0.07
35.52 ±
55.01
−111.74 ±
57.66 0.11 0.06
Resistin
(ng/mL)
55.67 ±
75.49
19.86 ±
20.43 0.34
−35.81 ±
83.28
14.41 ±
7.09
34.75 ±
34.55 0.04
20.34 ±
28.97
−56.15 ±
29.08 0.15 0.04
SE, standard error; p, p-value. Means and standard deviations are reported. * Wilcoxon sign-rank tests for differences
between baseline and follow up within groups. # Mann–Whitney tests for differences between groups at baseline.
¶ Mann–Whitney tests for differences in mean change between groups.
3.1. Effect of Carnosine Supplementation on Serum Adipokines
Change in serum resistin concentrations were significantly different between the carnosine
and placebo groups (mean change difference: −56.15 ± 29.08 ng/mL, p = 0.04), indicating a
reduction of resistin in the carnosine-treated individuals. A trend for reduced leptin concentrations
was observed after carnosine supplementation compared to placebo (mean change difference:
−111.74 ± 57.66 ng/mL, p = 0.06). There were no differences in change in adipsin concentrations
between the groups receiving carnosine and those receiving placebo (Table 1).
Nutrients 2018, 10, 1258 5 of 10
3.2. Associations between Carnosine Variables and Serum Adipokine Concentrations
Changes in both leptin and resistin concentrations were inversely correlated with a change in
urinary carnosine (r = −0.75, p = 0.001; r = −0.71, p = 0.0001, respectively), carnosine-propanal
(r = −0.56, p = 0.005; r = −0.63, p = 0.002, respectively) and carnosine-propanol concentrations
(r = −0.61, p = 0.002; r = −0.60, p = 0.002, respectively). Change in carnosinase-1 content or activity
were not correlated with either change in leptin or resistin concentrations (both p > 0.1).
Results of the median regression analyses are presented in Table 2. After adjustment for age, sex,
change in BMI, and intervention group, the observed associations for change in urinary carnosine
and carnosine-propanol with change in leptin and resistin remained significant (all p < 0.01; Table 2).
Similarly, carnosine-propanal remained associated with leptin concentrations (p = 0.01; Table 2);
however, the association with resistin was not longer significant (p = 0.1; Table 2).
Table 2. Multivariable quantile regression analyses for relationships between change in serum
adipokines and change in urinary carnosine levels.
Dependant Variable
Leptin (ng/mL) Resistin (ng/mL)
β 95% CI p β 95% CI p
Urinary carnosine (nmol/mL) −2.27 −3.38, −0.17 0.001 −1.52 −1.85, −1.18 <0.001
Carnosine-propanal (nmol/mL) −69.71 −126.46, −12.96 0.01 −24.01 −48.95, 0.92 0.05
Carnosine-propanol (nmol/mL) −67.96 −120.41, −15.51 0.01 −7.93 −19.02, 3.15 0.14
β, beta-coefficient; CI: confidence interval. Regression model: Relationship between change in leptin/resistin and
change in urinary carnosine or carnosine adducts after adjusting for age, sex, change in body mass index and
intervention group.
4. Discussion
To the best of our knowledge, this is the first study examining the effects of carnosine
supplementation on serum resistin, leptin, and adipsin concentrations in healthy humans. We found
that carnosine supplementation reduced serum resistin and leptin concentrations in overweight or
obese non-diabetic adults, and changes in serum resistin and leptin concentrations were inversely
associated with changes in urinary carnosine and carnosine adducts.
We report that carnosine supplementation reduced serum resistin and leptin concentrations
compared to placebo, and changes in urinary carnosine and carnosine adducts were inversely
associated with changes in leptin and resistin concentrations. To our knowledge, no previous animal or
human studies have examined relationships between carnosine and resistin or adipsin, nor the effects
of carnosine supplementation on these adipokines. Both resistin and adipsin have been implicated
in chronic low-grade inflammation and in the development of type 2 diabetes and cardiovascular
disease [22–24], hence further studies investigating the effects of carnosine on these adipokines are
warranted. Similarly, only one study examined the effects of carnosine on leptin [17], and did not show
any change in leptin concentrations. However, this study used a supplement which was a combination
of carnosine with cinnamon and chromium—some of which may have been biologically active [17].
In addition, the previous study [17] involved prediabetic, overweight and obese individuals who were
less obese than our cohort (average weight difference of more than 10 kg). Consistent with this,
baseline leptin concentrations in the previous study were lower (Mean= 31.0 ± 21.6 ng/mL in
the intervention group) compared to a baseline leptin concentration of 115 ± 146.5 ng/mL in the
carnosine group in our study, indicating a potentially higher degree of leptin resistance in our study
participants. It is therefore possible that carnosine supplementation may be more effective in reducing
leptin concentrations in the presence of greater obesity and higher leptin concentrations; however,
further studies are needed to confirm this.
There are several mechanisms by which carnosine supplementation may affect concentrations of
adipokines such as leptin and resistin, as was observed in our study. One potential mechanism occurs
via the effects of carnosine on oxidative stress. Carnosine has been shown to reduce systemic and tissue
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oxidative stress by reducing carbonylated proteins and advanced lipoxidation end products (ALEs),
decreasing the activity of superoxide dismutase and increasing the activity of liver enzymes [25–27].
These oxidative stress pathways have been shown to affect the synthesis and secretion of adipokines.
For instance, positive associations between leptin and markers of oxidative stress have been reported
in healthy middle-aged women and in non-diabetic hypercholesteremic patients [28,29]. Similarly,
in individuals with both obesity and type 2 diabetes, leptin was positively correlated with lipid
peroxidation and protein oxidation [30]. Resistin concentrations have been also associated with
markers of oxidative stress in healthy individuals [31], patients with type 2 diabetes [32], and in
patients undergoing cardiac surgery [33]. Carnosine may therefore improve adipokine concentrations
via reducing oxidative stress, and further studies investigating this mechanism are warranted.
A second possible mechanism is the commonly reported effects of carnosine on advanced
glycation end products (AGEs) [10]. Carnosine has been shown to prevent formation of AGEs and
ALEs and restrict any further glycation by both a non-enzymatic glycation and by a direct reaction with
reactive carbonyl species generated by lipid and sugar oxidation [34–37]. Studies have demonstrated
that AGEs/ALEs can affect the cellular function of adipocytes, particularly the synthesis and secretion
of adipokines [38,39]. In non-diabetic obese individuals, 4-hydroxynonenal, the main reactive carbonyl
species target of carnosine, was positively correlated with leptin [40]. AGE concentrations were
positively and independently associated with leptin concentrations in patients with type 2 diabetes [41].
Similarly, serum resistin concentrations were associated with soluble receptor for AGEs [42], suggesting
a potential link between resistin concentrations and AGEs. Hence, carnosine supplementation may
influence AGEs content in adipocytes, thereby regulating the synthesis and production of adipokines.
Finally, the anti-inflammatory properties of carnosine may also play a role in improving adipokine
concentrations. In vivo, administration of carnosine suppressed activation of nuclear factor kappa-B
(NF-κB), a transcription factor with a key role in inflammation and immunoregulation [43]. It has
been shown that the effects of both resistin [44] and leptin [45] are mediated by NF-κB activation.
Adipokines are also involved in the regulation of inflammatory responses. This is supported by
studies which reported positive associations between adipokines and markers of inflammation [46,47].
In morbidly obese individuals [46] and in dialysis patients [48], leptin concentrations were positively
correlated with concentrations of inflammatory markers including circulating CRP and tumor necrosis
factor. Serum resistin concentrations were also directly associated with markers of inflammation in
obese people [49] and post-menopausal women with rheumatoid arthritis [50]. However, we found no
associations between hsCRP and the adipokines measured in our study, and no effect of carnosine on
hsCRP concentrations [16], which is likely due to our small sample size and low concentrations of CRP
in our population. Nevertheless, it is possible that carnosine may regulate the release of adipokines
through inhibiting NF-κB activation and reducing inflammation markers, and this should be further
explored in larger intervention trials with carnosine supplementation.
This clinical trial has several strengths, including the use of rigorous methodology and a
double-blind randomized placebo-controlled design. This was the first study examining the effects of
carnosine supplementation on adipokine concentrations such as resistin, leptin and adipsin in humans.
The study participants were metabolically well-characterized, where there was no confounding by
disease status or medication use and no differences between groups at baseline. The main limitation of
this study was the small sample size as this was a pilot study, where adipokines were not the primary
outcome and there was no formal power calculation for adipokines. Further larger trials are needed to
confirm the effect of carnosine on adipokines. Moreover, participants in this study were overweight or
obese, non-diabetic adults, hence our results may not be generalizable to other populations including
lean adults or those with existing diseases.
5. Conclusions
We have shown for the first time that carnosine supplementation reduced serum resistin and
leptin concentrations in overweight or obese, otherwise healthy adults. These findings indicate the
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potential role of carnosine in the prevention and treatment of obesity-related cardiometabolic diseases
through reducing serum adipokines; however, further studies with larger sample sizes are needed to
confirm these preliminary results.
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